Protocol Ledger

NCT03624010 · Phase II · COMPLETED

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

Interventional Phase II clinical trial protocol NCT03624010 sponsored by Tenax Therapeutics in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-04-09 Enrollment: 35 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03624010
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)35 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03624010
Protocol FieldVerified Registry Value
NCT IdentifierNCT03624010
Consolidated Lead SponsorTenax Therapeutics
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment35 participants (ACTUAL)
Registered Start Date2019-04-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI